Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof, compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.磷脂醯肌醇(PI)3-激酶抑制劑化合物,其藥學上可接受之鹽及其前體藥物;此新穎化合物之組合物,無論是單獨或併用至少一種其他治療劑,與藥學上可接受之載劑;及該新穎化合物,無論是單獨或併用至少一種其他治療劑,於預防或治療增生疾病上之用途,該疾病之特徵為生長因子、蛋白質絲胺酸/蘇胺酸激酶及磷脂激酶之異常活性。
